Patient-recognition data-mining model for BCG-plus interferon immunotherapy bladder cancer treatment

Area of Science:

• Oncology
• Medical Informatics

Background:

• Bladder cancer is a prevalent malignancy in the US, incurring significant healthcare costs.
• Current treatment options for bladder cancer, including immunotherapy, have varying success rates.

Purpose of the Study:

• To analyze the effectiveness of bacillus Calmette-Guerin (BCG) plus interferon-alpha (IFN-alpha) immunotherapy for bladder cancer.
• To identify key parameters and their interactions influencing treatment outcomes using data mining.
• To develop a predictive model for patient treatment success.

Main Methods:

• Utilized data mining algorithms to analyze clinical trial data for BCG plus IFN-alpha immunotherapy.
• Developed a patient recognition model to predict treatment outcomes.
• Identified significant predictive parameters through data analysis.

Main Results:

• Identified significant parameters impacting bladder cancer treatment outcomes, including cumulative tumor size, residual disease, and prior/current cancer stages.
• The analysis provided insights into parameter interactions affecting treatment success.
• A predictive model for treatment outcomes was established.

Conclusions:

• The findings offer a comprehensive analytical roadmap for BCG/IFN-alpha immunotherapy in bladder cancer treatment.
• The study facilitates individualized treatment guidelines and success measurement for bladder cancer patients.
• Data mining provides valuable insights for optimizing immunotherapy efficacy.